GSK, UNC-Chapel Hill Partner To Establish Research Center, Company Aimed At Finding HIV/AIDS Cure

New York Times: Drugmaker and University Ally to Seek Cure for AIDS
“Years ago, curing AIDS was considered so out of the question that some scientists dared not even mention the possibility. But in the latest sign that attitudes are changing, the British pharmaceutical giant GlaxoSmithKline is teaming up with the University of North Carolina at Chapel Hill to start a research institute and a company aimed at curing HIV infection and AIDS…” (Pollack, 5/10).

Reuters: Hunt for AIDS cure accelerates as GSK and U.S. experts link up
“…GSK is tapping into the latest expertise by creating an HIV Cure center with the University of North Carolina (UNC) at Chapel Hill and establishing a new jointly owned company. The drugmaker said on Monday it would invest $20 million to help fund the work for an initial five years…” (Hirschler, 5/10).

Wall Street Journal: HIV Cure Is Goal of Glaxo-UNC Chapel Hill Partnership
“…The $20 million investment by Glaxo over five years comes on the heels of the company’s decision to retain its 78 percent stake in ViiV Healthcare, a business it owns jointly with Pfizer Inc. and Shionogi & Co. of Japan that develops drugs for HIV, the virus that causes AIDS. Taken together, the moves signal Glaxo’s ambition to play a major role in a new generation of HIV therapies, Glaxo Chief Executive Andrew Witty said in an interview…” (McKay, 5/10).